An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

Clinical trial NCT07517263 · RECRUITING

Trial details

NCT number: NCT07517263
Sponsor: Novartis Pharmaceuticals
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Cardiovascular Disease and Lipoprotein(a)

Start date: 2026-05-11
Primary completion: 2030-01-09
Enrollment: 5700

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.